Date post: | 09-Oct-2015 |
Category: |
Documents |
Upload: | igor-stefanet |
View: | 7 times |
Download: | 0 times |
of 27
5/19/2018 Cardiogenic_Shock.ppt
1/27
Cardiogenic Shock andHemodynamics
5/19/2018 Cardiogenic_Shock.ppt
2/27
Outline
Overview of shock
Hemodynamic Parameters
PA catheter, complications
Differentiating Types of Shock
Cardiogenic Shock
Etiologies
Pathophysiology
Clinical Findings
Treatment
5/19/2018 Cardiogenic_Shock.ppt
3/27
SHOCK= Inadequate Tissue Perfusion
Mechanisms: Inadequate oxygen delivery
Release of inflammatory mediators
Further microvascular changes, compromisedblood flow and further cellular hypoperfusion
Clinical Manifestations: Multiple organ failure
Hypotension
5/19/2018 Cardiogenic_Shock.ppt
4/27
Hemodynamic Parameters
Systemic Vascular Resistance (SVR)
Cardiac Output (CO) Mixed Venous Oxygen Saturation (SvO2)
Pulmonary Capillary Wedge Pressure
(PCWP)
Central Venous Pressure (CVP)
5/19/2018 Cardiogenic_Shock.ppt
5/27
Normal Values
Right Atrial
Pressure, CVP
Mean 0-6mmHg
Pulmonary
Artery Pressure
Systolic
End-diastolic
mean
15-30mmHg
4-12mmHg
9-19mmHg
PCWP Mean 4-12mmHgCardiac Output 4-8 L/min
Mixed Venous
O2 Sat
>70%
SVR 800-1200
5/19/2018 Cardiogenic_Shock.ppt
6/27
Differentiating Types of Shock
5/19/2018 Cardiogenic_Shock.ppt
7/27
PA Catheter Complications
Path of PAC: central venous circulation R
heart pulmonary artery. The proximal port is in
R atrium, distal port in pulm artery
Arrhythmias
RBBB
PA rupture
PAC related infection
Pulmonary infarction
5/19/2018 Cardiogenic_Shock.ppt
8/27
Cardiogenic Shock
Systemic hypoperfusion secondary to
severe depression of cardiac output andsustained systolic arterial hypotension
despite elevated filling pressures.
5/19/2018 Cardiogenic_Shock.ppt
9/27
Cardiogenic Shock
Etiologies
Pathophysiology Clinical/Hemodynamic Characteristics
Treatment Options
5/19/2018 Cardiogenic_Shock.ppt
10/27
Etiologies
Acute myocardialinfarction/ischemia
LV failure
VSR
Papillary muscle/chordalrupture- severe MR
Ventricular free wallrupture with subacute
tamponade
Other conditions complicating largeMIs
Hemorrhage
Infection
Excess negative inotropic orvasodilator medications
Prior valvular heart disease
Hyperglycemia/ketoacidosis
Post-cardiac arrest
Post-cardiotomy
Refractory sustainedtachyarrhythmias
Acute fulminant myocarditis
End-stagecardiomyopathyHypertrophiccardiomyopathy with severeoutflow obstruction
Aortic dissection with aorticinsufficiency or tamponade
Pulmonary embolu
Severe valvular heart disease -Critical aortic or mitral stenosis,Acute severe aortic or MR
5/19/2018 Cardiogenic_Shock.ppt
11/27
Pathophysiology
5/19/2018 Cardiogenic_Shock.ppt
12/27
Clinical Findings
Physical Exam: elevated JVP, +S3, rales,oliguria, acute pulmonary edema
Hemodynamics: dec CO, inc SVR, decSvO2
Initial evaluation: hemodynamics (PAcatheter), echocardiography, angiography
5/19/2018 Cardiogenic_Shock.ppt
13/27
4 Potential Therapies
Pressors
Intra-aortic Balloon Pump (IABP) Fibrinolytics
Revascularization: CABG/PCI
Refractory shock: ventricular assist device,
cardiac transplantation
5/19/2018 Cardiogenic_Shock.ppt
14/27
Pressors do not change outcome
Dopamine
5/19/2018 Cardiogenic_Shock.ppt
15/27
IABP is a temporizing measure
Augments coronary blood flow in diastole
Balloon collapse in systole creates a vacuum
effectdecreases afterload
Decrease myocardial oxygen demand
5/19/2018 Cardiogenic_Shock.ppt
16/27
Indication for IABP
5/19/2018 Cardiogenic_Shock.ppt
17/27
Contraindications to IABP
Significant aortic regurgitation or significant
arteriovenous shunting
Abdominal aortic aneurysm or aortic dissection
Uncontrolled sepsis
Uncontrolled bleeding disorder
Severe bilateral peripheral vascular disease Bilateral femoral popliteal bypass grafts for severe
peripheral vascular disease.
5/19/2018 Cardiogenic_Shock.ppt
18/27
Complications of IABP
Cholesterol Embolization
CVA Sepsis
Balloon rupture
Thrombocytopenia Hemolysis
Groin Infection
Peripheral Neuropathy
5/19/2018 Cardiogenic_Shock.ppt
19/27
Revascularization
SHOCK trial
Overall 30-Day Survival in the Study
Hochman J et al. N Engl J Med 1999;341:625-634
5/19/2018 Cardiogenic_Shock.ppt
20/27
SHOCK trial
Hochman J et al. N Engl J Med 1999;341:625-634
5/19/2018 Cardiogenic_Shock.ppt
21/27
Copyright restrictions may apply.
Hochman, J. S. et al. JAMA 2006;295:2511-2515.
Kaplan-Meier Long-term Survival of All Patients and Those Discharged Alive FollowingHospitalization
SHOCK 6 years later
5/19/2018 Cardiogenic_Shock.ppt
22/27
Question 1
5/19/2018 Cardiogenic_Shock.ppt
23/27
Answer
5/19/2018 Cardiogenic_Shock.ppt
24/27
Question 2
5/19/2018 Cardiogenic_Shock.ppt
25/27
Answer
5/19/2018 Cardiogenic_Shock.ppt
26/27
Question 3
5/19/2018 Cardiogenic_Shock.ppt
27/27
Answer